Study Sample

A packet consisting of a survey instrument, a cover letter, and a postage-paid return envelope without any financial or other incentive was mailed to a random sample of 690 physicians (625 excluding pediatricians) who were listed as members of the Minnesota Medical Association (MMA) (n = 460; 418 excluding pediatricians) or the North Dakota Medical Association (NDMA) (n = 230; 207 excluding pediatricians), respectively. We used a chi-square test for the equality of two proportions to determine the original sample size of 690.

…..Click here to read more

The Medicare drug benefit, introduced in 2006, is one of the largest changes in prescription coverage to ever take place in the U.S. The Part D benefit is enormously complex, and that complexity has implications for patients and physicians as well as policymakers.

…..Click here to read more

ABSTRACT

Background: The Medicare Part D program represents one of the largest changes in drug delivery to senior citizens in the U.S.; however, little is currently known regarding physician-patient communication about Part D.

…..Click here to read more

In clinical trials, a total of 578 patients received selegiline medication ODT. The most common adverse drug events reported, compared with placebo, were dizziness, nausea, pain, headache, insomnia, rhinitis, dyskinesia, back pain, stomatitis, and dyspepsia. Side effects that prompted discontinuation of therapy included dizziness, chest pain, accidental injury, and myasthenia.

…..Click here to read more

In an open-label extension study, Lew et al. evaluated the long-term safety, efficacy, and tolerability of adjunctive selegi-line ODT 2.5 mg in patients who completed either of two large phase 3 double-blind studies. The study had been scheduled to end after 12 months, but it was amended to be open-ended.

…..Click here to read more

A 12-week, multicenter, randomized, placebo-controlled trial was conducted to evaluate the safety and efficacy of selegiline tablet ODT as adjunctive therapy in patients with PD. A total of 140 patients were assigned to two treatment arms; 94 patients received selegiline ODT, and 46 patients received placebo.

…..Click here to read more

Selegiline HCl is a levo-rotatory acetyl-enic derivative of phenthylamine. It is chemically designated as (-)-(R)-N, a-dimethyl-N-2-propynylphenethyl-amine HCl. Its empirical formula is C₁₃H₁₇N • HCl, and its molecular weight is 223.75. Figure 1 illustrates the agent’s chemical structure.

…..Click here to read more